Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Curosurf dose comparison in neonates with respiratory distress syndrome
IRCT20210102049921N1Phase 3Completed
- Sponsor
- Vice Chancellor for Research, Birjand University of Medical Sciences
- Start
- Jun 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Poractant alfa in respiratory distress syndrome (RDS) (2 arms), sponsored by Vice Chancellor for Research, Birjand University of Medical Sciences. Primary endpoints: Duration of hospitalization, Treatment complications and 1 more. Started Jun 2021; status: completed.
02
Drugs
Poractant alfa
03
Conditions
respiratory distress syndrome (RDS)
Beyond the preview
Go deeper on IRCT20210102049921N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20210102049921N1.